Company / Current Assets
Tarsus Pharmaceuticals, Inc. Current Assets History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$522.8M
FY2025
5-year range
$176.0M / $522.8M
FY2021-FY2025
Trend
+46.6%
vs FY2024
Sector context
#113 of 213
Health Care
What the data says
At $523M, Tarsus Pharmaceuticals, Inc.'s current assets ranks #113 of 213 in the Health Care sector. Current Assets has increased for 6 consecutive years, from $58M in FY2019 to $523M in FY2025.
Based on SEC 10-K filings.
$523M in FY2025 with a 5-year CAGR of +25.1%.
Improved from $256M to $523M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +32.4%
- 5-Year CAGR
- +25.1%
- 10-Year CAGR
- -
Sector benchmark
#113 of 213 in Health CareTop 53% of 213This company $522.8M Sector average $2.5B
▼
-79.3% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s current assets has grown for 6 consecutive years.
- 5-year CAGR of +25.1%, indicating consistent growth.
- In FY2025, current assets increased 46.6% year-over-year.
- Ranks #113 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $522.8M | +46.6% |
| FY2024 | $356.7M | +39.3% |
| FY2023 | $256.1M | +13.6% |
| FY2022 | $225.4M | +28.1% |
| FY2021 | $176.0M | +3.1% |
| FY2020 | $170.7M | +194.1% |
| FY2019 | $58.0M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026